Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Enterprise Value for 7 consecutive years, with -$402.7 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value rose 5.23% to -$402.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$402.7 million through Dec 2025, up 5.23% year-over-year, with the annual reading at -$402.7 million for FY2025, 5.23% up from the prior year.
  • Enterprise Value for Q4 2025 was -$402.7 million at 4D Molecular Therapeutics, down from -$305.1 million in the prior quarter.
  • The five-year high for Enterprise Value was -$161.7 million in Q3 2021, with the low at -$541.9 million in Q2 2024.
  • Average Enterprise Value over 5 years is -$313.4 million, with a median of -$290.7 million recorded in 2023.
  • The sharpest move saw Enterprise Value crashed 162.36% in 2024, then soared 45.89% in 2025.
  • Over 5 years, Enterprise Value stood at -$247.8 million in 2021, then increased by 13.81% to -$213.6 million in 2022, then tumbled by 34.97% to -$288.2 million in 2023, then crashed by 47.41% to -$424.9 million in 2024, then rose by 5.23% to -$402.7 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$402.7 million, -$305.1 million, and -$293.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.